I S Sketris
Overview
Explore the profile of I S Sketris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris I, et al.
Clin Microbiol Infect
. 2019 Oct;
26(5):613-618.
PMID: 31655215
Objectives: The United States Food & Drug Administration released an advisory in 2016 that fluoroquinolones be relegated to second-line agents for uncomplicated urinary tract infections (UTIs) given reports of rare...
2.
Hill-Taylor B, Walsh K, Stewart S, Hayden J, Byrne S, Sketris I
J Clin Pharm Ther
. 2016 Mar;
41(2):158-69.
PMID: 26990017
What Is Known And Objective: STOPP/START are explicit screening tools that identify potentially inappropriate prescribing in older adults. Our objective was to update our 2013 systematic review that showed limited...
3.
Hill-Taylor B, Sketris I, Gardner D, Thompson K
J Popul Ther Clin Pharmacol
. 2016 Mar;
23(1):e1-12.
PMID: 26949844
Background: Optimization of prescribing in older adults is needed. The STOPP criteria provide a systematic way of identifying potentially inappropriate prescribing in this population. Previous research indicates poor concordance between...
4.
Sketris I, Fisher J, Langille Ingram E, Bergman U, Andersen M, Vlahovic-Palckevski V
J Popul Ther Clin Pharmacol
. 2012 May;
19(1):e78-98.
PMID: 22550125
Background: Drug therapy can improve patients' quality of life and health outcomes; however, underuse, overuse and inappropriate use of drugs can occur. Systematic examination of potential opportunities for improving prescribing...
5.
Sketris I, Maccara M, Purkis I, Curry L
Can Fam Physician
. 2011 Jan;
31:1591-6.
PMID: 21274169
The benzodiazepine prescribing habits of 64 maritime doctors were studied through collection and examination of carbon copies of all prescriptions over a 22 week period. Diazepam was the most frequently...
6.
Veugelers P, Fisk J, Brown M, Stadnyk K, Sketris I, Murray T, et al.
Mult Scler
. 2009 Dec;
15(11):1286-94.
PMID: 19965558
Randomized controlled trials have demonstrated the efficacy of disease-modifying drugs (DMDs) in persons with relapsing-remitting multiple sclerosis (MS) and secondary progressive MS with superimposed relapses. However, these brief studies of...
7.
Brenner S, Brown M, Kirby S, Skedgel C, Fisk J, Murray T, et al.
Neurology
. 2008 Aug;
71(8):615.
PMID: 18711118
No abstract available.
8.
Brown M, Kirby S, Skedgel C, Fisk J, Murray T, Bhan V, et al.
Neurology
. 2007 Aug;
69(15):1498-507.
PMID: 17699802
Objective: Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset (R-onset) definite MS patients under "real-world" conditions. Methods: Treatment...
9.
Whelan A, Cooke C, Sketris I
J Clin Pharm Ther
. 2005 Apr;
30(2):165-71.
PMID: 15811170
Objective: To determine whether any demographic or socioeconomic factors affect the use of smoking cessation medications in patients hospitalized with heart disease. Method: Data were obtained from the Improving Cardiovascular...
10.
Fisk J, Brown M, Sketris I, Metz L, Murray T, Stadnyk K
J Neurol Neurosurg Psychiatry
. 2004 Dec;
76(1):58-63.
PMID: 15607996
Objectives: To evaluate the practical application and psychometric properties of three health utility measures in a sample of MS patients with a broad range of neurological disability as measured by...